INDIANOLA, Pa., Nov. 17 /PRNewswire/ -- Improved CT diagnostic images of
the coronary arteries are possible with fewer artifacts; this is the focus of
MEDRAD's live booth presentation of the Stellant(R) CT Injection System at the
2004 Annual Meeting of the Radiological Society of North America (RSNA). The
presentation will repeat every hour and offer clinical information, real-world
examples, physician testimonials, and product demos on how to achieve better
CT imaging results with DualFlow(TM) Simultaneous Injection (Booth #1929,
South Building).
(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )
Stellant is designed to meet the latest clinical, safety and ease-of-use
requirements of rapidly evolving computed tomography (CT) technology. The
Stellant D with the DualFlow(TM) option enables both contrast and saline
injection at the same time through variable ratios of simultaneous plunger
motion. With the proper ratio and timing, left and right heart ventricles can
be illuminated uniformly.
"Stellant is a prime example of MEDRAD's commitment to product innovation,
and clinicians have responded enthusiastically," according to Cliff Kress,
senior vice president of the MEDRAD CT Strategic Business Unit. "DualFlow's
contribution to diagnostic capabilities, combined with the rapid growth in
complicated CTA and CT Cardiac procedures, creates a very valuable solution
for our customers."
Designed with input from radiology thought leaders around the world,
Stellant also features a pressure monitor graph, improved syringe design,
syringe auto load and the ability to upgrade from single to dual injection.
MEDRAD, Inc. is a worldwide leading provider of medical devices and
services that enable and enhance imaging procedures of the human body. Used in
diagnostic imaging, MEDRAD's product offerings include a comprehensive line of
vascular injection systems, magnetic resonance (MR) surface coils and
accessory products, and equipment services. Total 2003 revenues were
$294 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National
Quality Award, the top honor a U.S. company can receive for quality and
business excellence. The company's world headquarters is near Pittsburgh,
Pennsylvania, in the United States. MEDRAD is a U.S. affiliate of Schering AG,
Germany (NYSE: SHR). For more information, visit MEDRAD's website
at http://www.medrad.com .
Cautionary statement regarding forward-looking statements.
Certain statements in this press release that are neither reported
financial results nor other historical information are forward-looking
statements, including but not limited to, statements that are predictions of
or indicate future events, trends, plans or objectives. Undue reliance should
not be placed on such statements because, by their nature, they are subject to
known and unknown risks and uncertainties and can be affected by other factors
that could cause actual results and MEDRAD's plans and objectives to differ
materially from those expressed or implied in the forward-looking statements.
MEDRAD undertakes no obligation to update publicly or revise any of these
forward-looking statements, whether to reflect new information or future
events, circumstances or otherwise.
SOURCE MEDRAD, Inc.
 back to top
Related links:
http://www.medrad.com
http://www.rsna.org/rsna/index.html
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Luanne Radermacher, Corporate Communications,
+1-412-767-2400, ext. 3184, or lradermacher@medrad.com , or Dan
Dieter, Marketing Services, +1-412-767-2400 ext. 3726, or
ddieter@medrad.com , both of MEDRAD, Inc.
|
